The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2020 | Burning questions: ASCT in AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the burning questions in the use of autologous stem cell transplant (ASCT) in AL amyloidosis. The successful use of novel agents and data drawn from the ANDROMEDA trial (NCT03201965) is referenced as to why the utility of ASCT in AL amyloidosis may be questioned. However, Dr Sanchorawala does go on to explain how for a small patient population, ASCT is still a very useful tool. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
